Financial Performance - As of September 30, 2025, total assets decreased to $832,159 thousand from $903,330 thousand as of December 31, 2024, representing a decline of approximately 7.9%[18] - Total current assets decreased to $814,022 thousand, down from $891,211 thousand, a reduction of about 8.7%[18] - The net loss attributable to ordinary shareholders for the three months ended September 30, 2025, was $65,712 thousand, compared to a net loss of $33,977 thousand for the same period in 2024, reflecting a 93.3% increase in losses[21] - The company reported a comprehensive loss of $65,249 thousand for the three months ended September 30, 2025, compared to a comprehensive loss of $30,651 thousand for the same period in 2024, indicating a significant increase in overall losses[21] - For the nine months ended September 30, 2025, Structure Therapeutics reported a net loss of $174.2 million, compared to a net loss of $86.0 million for the same period in 2024, representing a 102% increase in losses year-over-year[27] - Total operating expenses for the nine months ended September 30, 2025, were $200.5 million, up from $111.2 million in the same period of 2024, indicating an increase of 80%[42] - The company reported a net cash used in operating activities of $157.8 million for the nine months ended September 30, 2025, compared to $80.2 million for the same period in 2024, marking a 97% increase[27] - The company incurred significant research and development expenses, with discovery research and development costs amounting to $72.6 million for the nine months ended September 30, 2025, compared to $37.8 million in 2024, reflecting a 92% increase[42] - The company has incurred net operating losses since inception, with an accumulated deficit of $503.3 million as of September 30, 2025[105]. Assets and Liabilities - Total liabilities increased to $62,140 thousand as of September 30, 2025, from $38,487 thousand as of December 31, 2024, marking an increase of approximately 61.5%[18] - The accumulated deficit as of September 30, 2025, was $(503,304) thousand, compared to $(329,098) thousand as of December 31, 2024, indicating a worsening of the deficit by approximately 52.9%[23] - As of September 30, 2025, the company had cash, cash equivalents, and short-term investments totaling $799.0 million, which is expected to fund operations for at least the next 12 months[36] - The company has classified $549.7 million of investments as short-term, with remaining contractual maturities within one year[57] - The total fair value of financial assets is $791.553 million, compared to $875.336 million as of December 31, 2024[57]. Research and Development - Research and development expenses for the three months ended September 30, 2025, were $58,989 thousand, an increase of 80.7% compared to $32,598 thousand for the same period in 2024[21] - The company expects to continue incurring significant operating losses as it invests in research and development and expands its product pipeline[108] - Research and development expenses for the nine months ended September 30, 2025, increased by $81.2 million, or 108%, totaling $156.6 million, primarily due to clinical trial costs and increased personnel expenses[125][126]. - Aleniglipron demonstrated a statistically significant placebo-adjusted mean decrease in weight of 6.2% at 12 weeks in a Phase 2a obesity study[90] - The Phase 2b ACCESS study for aleniglipron involves approximately 220 participants, with a primary endpoint of percent change in body weight from baseline to week 36[93] - The ongoing ACCESS II study will extend to 44 weeks, allowing for additional data collection on safety and efficacy[96] - ACCG-2671, a lead development candidate, is expected to initiate a first-in-human Phase 1 clinical study by year-end 2025[98] - In November 2025, ACCG-3535 was selected as a second DACRA development candidate, demonstrating significant body weight reduction in preclinical studies[99] - LTSE-2578 completed a Phase 1 clinical study with no serious adverse events observed, indicating favorable safety and tolerability[100] - ANPA-0073 is currently conducting long-term GLP-toxicology studies and is Phase 2 ready for use in combination with weight loss medicines[101]. Capital and Financing - The company completed a Private Placement on October 3, 2023, raising net proceeds of approximately $281.5 million from the sale of 21,617,295 ordinary shares[31] - Structure Therapeutics closed its Follow-On Offering on June 7, 2024, generating net proceeds of approximately $512.7 million from the issuance of 10,427,017 ADSs[32] - The company raised approximately $166.7 million in net cash proceeds from its IPO in February 2023 by issuing 12,351,000 American Depositary Shares (ADSs) at $15.00 per ADS[129] - The company may seek additional capital through public or private equity sales, grants, or strategic collaborations to support its operations and product development[108] - The company anticipates needing substantial additional capital to fund ongoing operations and product development, particularly for Phase 3 clinical studies[133]. Clinical Development Challenges - The company faces challenges in clinical development, including potential delays in obtaining regulatory approvals and recruiting suitable patients[185] - Patient enrollment is significantly impacted by the size and nature of the patient population, with challenges in locating and enrolling eligible patients for clinical studies[190] - Delays in patient enrollment or retention can lead to increased costs and program delays, adversely affecting the ability to develop product candidates[195] - Serious adverse events or unexpected properties of product candidates could lead to the discontinuation of clinical programs or refusal of regulatory approval, limiting commercial potential[196] - The lengthy and unpredictable marketing approval process by the FDA may result in failure to obtain necessary approvals, significantly harming the business[206]. Regulatory and Market Considerations - The company intends to pursue orphan drug designation for one or more of its product candidates, which is crucial for its business strategy[215] - Orphan drug designation may provide a seven-year period of marketing exclusivity, preventing other applications for the same chemical entity during this period[214] - Regulatory authorities may require additional studies or disagree on product specifications, potentially delaying marketing approval[212] - The company is at risk of losing orphan drug exclusive marketing rights if it cannot assure sufficient product quantity[215] - The FDA's approval policies may change, affecting the sufficiency of clinical data for approval[212].

Financial Performance - Net sales for the three months ended September 30, 2025, decreased by $3.5 million, or 4.1%, to $81.6 million compared to $85.1 million in the same period of 2024[110]. - Gross profit decreased to $32.4 million for the three months ended September 30, 2025, down from $37.3 million in the prior year, with gross margin declining to 39.7% from 43.9%[112]. - Net loss for the three months ended September 30, 2025, was $4.0 million, a 19.5% improvement from a net loss of $5.0 million in the same period of 2024[109]. - EBITDA improved by $0.7 million to a loss of $0.8 million for the three months ended September 30, 2025, compared to a loss of $1.4 million in the prior year[105]. - For the three months ended September 30, 2025, the company reported a net loss of $4.025 million, an improvement from a net loss of $5.002 million in the same period of 2024[123]. - Adjusted EBITDA for the three months ended September 30, 2025, was $1.364 million, compared to $1.417 million in 2024, with an Adjusted EBITDA Margin of 1.7% for both periods[124]. Operating Expenses - Operating expenses decreased by $4.5 million to $35.6 million, representing 43.6% of net sales, down from 47.2% in the prior year[113]. - Selling expenses decreased by $1.4 million, while general and administrative expenses decreased by $2.5 million in the three months ended September 30, 2025[113]. - Interest expense decreased by $0.5 million to $1.3 million for the three months ended September 30, 2025, primarily due to lower pension-related interest costs[115]. Sales and Pricing - Average unit price increased by 7.7% while unit sales decreased by 10.9% in the three months ended September 30, 2025, contributing to the overall decline in net sales[111]. - The company did not introduce any new product categories that materially impacted net sales during the three months ended September 30, 2025[111]. Cash Flow and Capital Expenditures - Net cash used in operating activities was $5.007 million for the three months ended September 30, 2025, a decrease of $7.5 million compared to net cash provided of $2.493 million in 2024[138]. - Total capital expenditures for the three months ended September 30, 2025, were $1.9 million, a decrease of 42.0% from $3.3 million in the prior year[105]. - Capital expenditures for the three months ended September 30, 2025, were $1.9 million, down from $3.3 million in the same period of 2024[141]. - The company anticipates paying between $9.0 million to $11.0 million in capital expenditures in fiscal 2026, financed through cash flows from operations and borrowings[141]. Inventory and Borrowings - The company had outstanding borrowings of $18.3 million on its Revolver Credit Facility as of September 30, 2025, with a weighted average interest rate of 6.15%[132]. - The company had committed to purchase green coffee inventory totaling $31.6 million under fixed-price contracts as of September 30, 2025[143]. - As of September 30, 2025, the company had $3.8 million in unrestricted cash and cash equivalents, and $31.2 million available on its Revolver Credit Facility[136]. Market Conditions - The company continues to monitor macroeconomic trends, including product cost inflation and tariff impacts, which may adversely affect net sales and profitability[130]. - The company operates a nationwide DSD network with over 200 delivery routes and over 90 storage locations as of September 30, 2025[129].

ClearPoint Neuro Reports Third Quarter 2025 Results Site Readiness Continues for Specialized Treatment Centers Envisioned to Support a Growing Number of Cell and Gene Therapy Trial Patients and Later Commercialization • Continued to provide supply, development, and strategic support to more than 60 active biopharma partners, including nine partner programs accepted for FDA expedited review, with many partners sharing updates on their scientific and regulatory progress at the 2025 ESGCT Annual Congress in Se ...

Financial Performance - Net income for Q3 2025 was $19.4 million ($0.82 per share), up from $17.5 million ($0.78 per share) in Q3 2024, reflecting a 10.9% increase in net income year-over-year[3]. - Adjusted net income for the first nine months of 2025 was $94.9 million ($4.06 per share), compared to $84.2 million ($3.76 per share) in the prior-year period, resulting in an 8.0% growth in adjusted EPS[5]. - The company reported a 10.1% growth in net income and a 10.9% growth in adjusted EPS for the first nine months of 2025 compared to the prior-year period[5]. - Adjusted net income for Q3 2025 was $19.5 million, up from $18.1 million in Q3 2024, representing a 7.7% increase[36]. - Adjusted earnings per share (EPS) for Q3 2025 increased to $0.82 from $0.80 in Q3 2024, reflecting a 2.5% growth[36]. - For the nine months ended September 30, 2025, adjusted net income was $94.9 million, compared to $84.2 million for the same period in 2024, marking a 12.8% increase[37]. - Net income for the nine months ended September 30, 2025, was $94.2 million, up 15.0% from $81.9 million in the same period of 2024[64]. Revenue and Margin Growth - Adjusted gross margin increased by $15.2 million for Q3 2025 and $49.3 million for the nine-month period, driven by organic growth in natural gas distribution and infrastructure programs[6]. - The company generated over $20 million of gross margin from transmission, infrastructure, and transportation projects during Q3 2025[9]. - Adjusted gross margin for Q3 2025 was $137.2 million, an increase of $15.2 million or 12.5% compared to Q3 2024[19]. - For the nine months ended September 30, 2025, adjusted gross margin reached $462.4 million, up $49.3 million or 11.9% from $413.1 million in 2024[25]. - The total adjusted gross margin for nine months ended September 30, 2025, was $130.1 million, up from $115.2 million in 2024, indicating a 12.9% growth[37]. - Increased contributions from regulated infrastructure programs added $11.0 million to adjusted gross margins for the nine months ended September 30, 2025[37]. Operating Income and Expenses - Operating income for Q3 2025 was $45.0 million, reflecting a $4.1 million increase or 10.0% from the same period in 2024[19]. - Operating income for the nine months ended September 30, 2025, was $182.1 million, an increase of $20.8 million or 12.9% compared to the same period in 2024[25]. - The company experienced higher operating expenses due to increased depreciation and the absence of RSAM adjustments, which had previously provided benefits of $8.9 million in 2024[26]. - Total operating expenses for Q3 2025 were $134.6 million, up from $119.3 million in Q3 2024, marking a 12.5% increase[64]. - Operating expenses increased by $30.1 million for the nine months ended September 30, 2025, primarily due to depreciation and maintenance costs[37]. Capital Expenditures and Guidance - Capital guidance for 2025 has been increased to a range of $425 million to $450 million, reflecting ongoing investments in infrastructure and projects[10]. - The company continues to affirm its 2028 EPS guidance range of $7.75 to $8.00 per share, along with a capital expenditure guidance of $1.5 billion to $1.8 billion for the five-year period ending 2028[11]. - The Company's capital expenditures for the nine months ended September 30, 2025, were $335.6 million, with a forecasted range for 2025 capital expenditures between $425 million and $450 million[60]. Customer Growth and Consumption - The average number of residential customers served on the Delmarva Peninsula increased by approximately 4.3% for the nine months ended September 30, 2025[58]. - Average Residential Customers for Delmarva NG grew to 106,028 in Q3 2025 from 101,635 in Q3 2024, an increase of 4.0%[71]. - Average Commercial and Industrial Customers for Florida Natural increased to 8,445 in Q3 2025 from 8,322 in Q3 2024, showing a growth of 1.5%[71]. - Increased customer consumption due to colder weather conditions resulted in a $4.8 million increase in adjusted gross margin for the nine months ended September 30, 2025[54]. Regulatory and Project Updates - The company has ongoing regulatory initiatives expected to contribute $56.0 million to adjusted gross margins in 2026[40]. - The Maryland natural gas distribution businesses achieved a cumulative increase of $3.5 million in annual base rates following a settlement approved in April 2025[48]. - The Delaware natural gas division filed for a permanent rate relief of approximately $12.1 million, with annualized interim rates of $2.5 million approved in October 2024[51]. - The Florida Electric division's general base rate increase of $12.6 million was settled for a total revenue increase of approximately $8.6 million annually, effective July 2025[52]. - Major projects, including pipeline expansions, are expected to generate an estimated $46.1 million in adjusted gross margin in 2026[40]. - The Worcester Resiliency Upgrade project is projected to generate $10.2 million in adjusted gross margin in 2026 and $17.6 million in 2027[42]. - The East Coast Reinforcement Projects in Boynton Beach and New Smyrna Beach will provide an additional 15,000 Dts/day and 3,400 Dts/day of supply, respectively[43]. - Peninsula Pipeline's projects in Central Florida will add 5,000 Dts/day and 8,700 Dts/day to FPU's distribution system, with completion expected in 2024 and 2025 respectively[44]. - The renewable natural gas projects in Florida are projected to enhance FCG's gas supply and system reliability, with completion expected in the first half of 2026[45]. Equity and Debt Position - The company's equity to total capitalization ratio was approximately 49% as of September 30, 2025, as it aims to return to a target ratio of 50-60%[61]. - Stockholders' equity rose to $1,518.7 million as of September 30, 2025, up from $1,390.2 million at the end of 2024, indicating a 9.2% increase[67]. - Long-term debt (net of current maturities) increased to $1,437.9 million as of September 30, 2025, compared to $1,261.7 million at the end of 2024, reflecting a 14.0% increase[67].

Acquisition Strategy - As of September 30, 2025, the company has acquired nine insurance agencies as part of its aggressive acquisition strategy[96] - The company has extensive experience in acquiring and managing insurance portfolios, focusing on undervalued agencies in growing or underserved segments[95] Market Expansion and Digital Initiatives - The company plans to focus on geographic expansion and market share growth over the next 12 months, alongside its Digital Asset Treasury Initiative[97] - The 5MinuteInsure.com platform operates in 46 states, allowing consumers to compare quotes from up to 30 insurance carriers in approximately 5 minutes[99] - The RELI Exchange platform has increased its agent roster by over 300% since its inception, enhancing the company's B2B capabilities[100] - The company aims to tokenize insurance-linked assets, potentially creating a new investment class that increases transparency and liquidity in the insurance market[101] - The company has adopted a "OneFirm" strategy to enhance cross-selling and operational efficiency across its agencies[102] Financial Performance - Commission Income decreased by 27% to $2,495,975 from $3,441,458, primarily due to loss of revenue from the sale of Fortman Insurance Services[130] - Salaries and wages increased by 129% to $3,912,326 from $1,707,737, influenced by non-cash share-based compensation[130] - General and administrative expenses rose by 36% to $1,120,776 from $821,510, driven by director non-cash equity awards[130] - Total operating expenses increased by 62% to $6,409,658 from $3,953,435, reflecting overall operational changes[130] - Loss from operations significantly increased by 664% to $(3,913,683) from $(511,977)[130] - Interest expense decreased by 31% to $(246,722) from $(356,320) due to payoffs on loan balances[130] - Gain on sale of business amounted to $3,033,554, reflecting a significant increase compared to the previous period[131] - AEBITDA improved to $(707,021) from $(749,530), indicating a positive trend in operational efficiency[131] - Other income decreased by 125% to $(16,470) from $65,785, primarily due to fluctuations in digital asset valuations[131] - The company is focusing on market expansion and operational efficiencies to mitigate losses and improve financial performance[130] - Commission Income decreased by 8.72% to $9,818,872 compared to $10,757,238 in the previous year[132] - Salaries and Wages increased by 58% to $8,705,682, primarily due to the elimination of "FIS" salaries[132] - General and Administrative expenses rose by 30% to $4,129,842, driven by director non-cash equity awards[132] - Loss from operations increased by 15% to $(7,692,638) compared to $(6,690,278) in the previous year[132] - Interest expense decreased by 23% to $(844,846) due to payoffs on the majority of loan balances[132] - Gain on sale of business (FIS) amounted to $3,033,554, reflecting a significant increase[133] - Total operating expenses remained relatively stable at $17,511,510, with a slight increase of 0% compared to the previous year[132] - AEBITDA showed a significant decline of 339% to $(918,706) from $(209,113) in the previous year[133] - Asset impairment was recorded at $0, a decrease of 100% from $3,922,110 in the previous year[132] - Marketing and Advertising expenses decreased by 34% to $201,399, aligning with the company's current marketing strategy[132] - For the nine months ended September 30, 2025, the company reported a net loss of approximately $5.6 million, an improvement from a net loss of approximately $7.7 million for the same period in 2024[134] - The company achieved AEBITDA of approximately $(918,706) for the nine months ended September 30, 2025, compared to $(209,114) for the same period in 2024[134] Capital and Financing Activities - The company entered into a Common Stock Purchase Agreement allowing it to sell up to $10 million of newly issued shares to White Lion Capital, enhancing its capital resources[113] - The company issued 450,000 shares of Common Stock for net proceeds of approximately $350,000, with an additional 300,000 shares issued post-quarter for approximately $300,000, leaving a remaining capacity of approximately $9.3 million under the ELOC[115] - The company sold 1,853,048 shares under the At-the-Market Program, generating net proceeds of approximately $2,021,681 after deducting sales commissions and offering expenses[117] - The company entered into a Private Placement agreement for the purchase of up to 1,488,096 shares at an exercise price of $0.001 per share, and up to 2,976,192 shares at an exercise price of $1.43 per share[118] - The company issued $100,000 of fully earned common stock as commitment shares in two tranches, with the first tranche of $50,000 issued as of September 30, 2025[114] - The company executed Amendment No. 1 to the Common Stock Purchase Agreement with White Lion Capital, allowing for a Fixed Purchase Notice option to sell shares at a price equal to 90% of the lowest traded price during a specified time[116] - The company intends to use net proceeds from the ATM Program for general corporate purposes[117] - The company has filed a registration statement on Form S-1 for the resale of shares issuable under the White Lion Agreements, which was declared effective on September 4, 2025[114] - The company raised approximately $4.5 million in net proceeds through equity financing programs during the nine months ended September 30, 2025, including $2.0 million from the ATM Program and $2.1 million from the Private Placement-2025[137] - The company has approximately $9.3 million of capacity remaining under the Equity Line of Credit as of September 30, 2025[138] Cash Flow and Liquidity - As of September 30, 2025, the company had a total cash balance of approximately $3.5 million, an increase from approximately $1.8 million as of December 31, 2024[140] - Cash flows provided by investing activities were approximately $4.3 million for the nine months ended September 30, 2025, compared to cash flows used of approximately $58,787 for the same period in 2024[145] - The company experienced a net cash used in operating activities of approximately $1.5 million for the nine months ended September 30, 2025, a slight improvement from $1.6 million for the same period in 2024[144] - The company reported a significant increase of approximately 590% in unrestricted cash since the fiscal year-end 2024[137] - Management intends to utilize net proceeds from financing for general corporate purposes, including working capital and technology development[139] Economic Outlook - The company anticipates that inflation may materially impact pricing and operating expenses in future periods[141]

Financial Performance - Citigroup reported net income of $3.8 billion, or $1.86 per share, for Q3 2025, up from $3.2 billion, or $1.51 per share in the prior-year period, reflecting a 16% increase[33]. - Revenues for Q3 2025 were $22.1 billion, a 9% increase compared to the prior-year period, driven by growth across all five business segments and Legacy Franchises[35]. - The company reported a net income of $3,752 million for Q3 2025, a 16% increase from $3,238 million in Q3 2024[86]. - Earnings per share (EPS) from continuing operations rose to $1.89 in Q3 2025, up 24% from $1.53 in Q3 2024[86]. - Net income for Q3 2025 was $3.75 billion, reflecting a 16% increase compared to $3.24 billion in Q3 2024[96]. - Net income for 2025 YTD reached $4.8 billion, a 5% increase, driven by higher revenues, partially offset by higher provisions[115]. - Net income for 2025 YTD reached $5.1 billion, a 29% increase driven by higher revenues, partially offset by increased expenses[135]. - Net income for 2025 YTD reached $1.6 billion, a 41% increase driven by higher revenues and lower expenses[154]. - For the year-to-date 2025, net income reached $2.3 billion, a 127% increase compared to the same period in 2024[193]. Revenue Growth - Average loans increased to $725 billion, up 6% year-over-year, primarily due to growth in Markets and U.S. Personal Banking[36]. - Average deposits rose to approximately $1.4 trillion, a 5% increase year-over-year, driven by growth in Services[37]. - Total Citigroup net revenues for Q3 2025 were $22.09 billion, a 9% increase from $20.21 billion in Q3 2024[95]. - Non-interest revenue increased by 4% to $7,150 million in Q3 2025, compared to $6,847 million in Q3 2024[86]. - Services revenue increased by 7% to $5.36 billion in Q3 2025, driven by higher net interest income and fee revenue[102]. - Total revenues for the third quarter increased by 15%, reaching $5.6 billion, driven by higher revenues in both Fixed Income and Equity Markets[130]. - Revenues increased by 14%, with Fixed Income Markets and Equity Markets contributing significantly to this growth[135]. - Revenues increased by 21% to $2.164 billion, with Corporate Lending revenues up 26% and Investment Banking revenues up 17%[155][156]. Expenses and Efficiency - Operating expenses were $14.3 billion, a 9% increase, influenced by a notable goodwill impairment of $726 million and higher compensation expenses[38]. - The efficiency ratio improved to 50% in Q3 2025, down from 51% in Q3 2024[101]. - The efficiency ratio improved to 53% from 70% year-over-year, indicating better cost management[141]. - Total operating expenses increased by 4% to $1.654 billion, influenced by higher technology investments and volume-related expenses[171]. - Total operating expenses in Q3 2025 were $2,168 million, compared to $2,077 million in Q3 2024, indicating an increase of approximately 4.4%[201]. - Total operating expenses for the nine months ended September 30, 2025 were $6,668 million, compared to $6,868 million in 2024, a decrease of about 2.9%[201]. Capital and Shareholder Returns - Citi returned approximately $6.1 billion to common shareholders, including $5.0 billion in share repurchases and $1.1 billion in dividends[39]. - As of September 30, 2025, Citi's Common Equity Tier 1 (CET1) Capital ratio was 13.3%, approximately 120 basis points above its regulatory requirement[39]. - Citigroup's common share repurchases increased significantly to $5,000 million in Q3 2025, compared to $1,000 million in Q3 2024, marking a 400% increase[86]. Credit Losses and Provisions - Total provisions for credit losses were $2.5 billion, reflecting net credit losses of $2.2 billion, which was up 2% from the prior-year period[40]. - Provisions in All Other (managed basis) were $331 million, reflecting net credit losses of $297 million, which was up 43% from the prior-year period[76]. - Total provisions for credit losses were $1.8 billion in Q3 2025, reflecting net credit losses of $1.8 billion, down 5% from the previous year[191]. - Provisions for credit losses were $465 million, reflecting a net ACL build of $428 million, primarily due to transfer risk associated with Russia[120]. - Provisions for credit losses were $157 million, reflecting a net ACL build of $148 million and net credit losses of $9 million[152]. - Provisions for credit losses were $30 million, reflecting net credit losses of $56 million and a net ACL release of $26 million[172]. Business Segment Performance - Markets net income increased 46% to $1.6 billion, with revenues of $5.6 billion up 15%, driven by a 12% increase in Fixed Income Markets and a 24% increase in Equity Markets[52][53]. - Banking revenues increased 34% to $2.1 billion, driven by growth in Corporate Lending and Investment Banking, with Investment Banking revenues up 23%[58]. - Wealth revenues increased 8% to $2.2 billion, driven by growth in Citigold and the Private Bank, with net interest income up 8%[63]. - US Personal Banking (USPB) revenues increased 7% to $5.3 billion, driven by growth in Branded Cards and Retail Banking[68]. - All Other (managed basis) revenues decreased 16% to $1.5 billion, driven by lower revenues in Corporate/Other[74]. - TTS revenues increased by 7%, driven by a 14% increase in net interest income, partially offset by a 15% decrease in non-interest revenue[109]. - Securities Services revenues increased by 7%, with a 14% rise in non-interest revenue driven by a mark-to-market gain and a 13% increase in AUC/AUA[110]. - Fixed Income Markets revenues increased by 12%, driven by growth in Rates and Currencies revenues[131]. - Equity Markets revenues rose by 24%, attributed to higher client activity in Equity Derivatives and a 44% increase in prime balances[132]. Transformation and Technology Investments - The company continued to invest in transformation and technology, which contributed to higher performance-related compensation and severance costs[38]. - Citigroup's transformation investments are expected to be significantly higher in 2025 compared to 2024, focusing on data and controls[81]. - Approximately 7 million utilizations of Citi's enterprise-wide Generative AI tools were recorded year-to-date, a threefold increase from the previous quarter[84]. - The company continues to optimize its operations by retiring or replacing 384 applications year-to-date through September 30, 2025[84]. Goodwill Impairment - The company reported a goodwill impairment charge of $726 million in Q3 2025, significantly impacting operating expenses[202].

Financial Performance - Total current assets decreased from $357,103,000 as of December 31, 2024, to $290,828,000 as of September 30, 2025, a decline of approximately 18.5%[14] - Collaboration revenue for the three months ended September 30, 2025, was $2,054,000, compared to $0 for the same period in 2024, indicating a significant increase[15] - Net loss for the three months ended September 30, 2025, was $20,171,000, compared to a net loss of $23,407,000 for the same period in 2024, showing an improvement of approximately 9.4%[15] - The company reported a total comprehensive loss of $54,632,000 for the nine months ended September 30, 2025, compared to $49,925,000 for the same period in 2024, indicating an increase in overall losses[15] - The company reported a net loss of $54.7 million for the nine months ended September 30, 2025, compared to a net loss of $50.0 million for the same period in 2024[22] - The net loss attributable to common stockholders for the three months ended September 30, 2025, was $20.2 million, compared to a net loss of $23.4 million for the same period in 2024, representing a decrease of approximately 13.5%[11] - For the nine months ended September 30, 2025, the net loss was $54.7 million, compared to $50.0 million for the same period in 2024, indicating an increase of approximately 9.4%[11] Expenses - Research and development expenses for the nine months ended September 30, 2025, rose to $49,466,000, up from $39,811,000 in 2024, reflecting a 24.5% increase[15] - Total operating expenses for the nine months ended September 30, 2025, were $70,274,000, compared to $52,832,000 in 2024, representing a 33.1% increase[15] - General and administrative expenses rose by $7.8 million, or 60%, from $13.0 million for the nine months ended September 30, 2024 to $20.8 million for the same period in 2025[162] - Research and development expenses increased by $9.7 million, or 24%, from $39.8 million for the nine months ended September 30, 2024 to $49.5 million for the same period in 2025[160] - Stock-based compensation expense increased to $8.97 million for the nine months ended September 30, 2025, from $4.26 million in the prior year[22] - Research and development expenses decreased by $1.5 million from $20.0 million for the three months ended September 30, 2024, to $18.5 million for the same period in 2025, primarily due to a $13.1 million reduction in azelaprag direct costs[154] - General and administrative expenses increased by $2.0 million from $4.7 million for the three months ended September 30, 2024, to $6.7 million for the same period in 2025, driven by increased legal fees and personnel-related expenses[155] Assets and Liabilities - Total liabilities decreased from $35,107,000 as of December 31, 2024, to $27,626,000 as of September 30, 2025, a reduction of about 21.1%[14] - Stockholders' equity decreased from $323,127,000 as of December 31, 2024, to $277,464,000 as of September 30, 2025, a decline of approximately 14.1%[14] - Cash and cash equivalents decreased from $354,349,000 as of December 31, 2024, to $215,573,000 as of September 30, 2025, a decline of approximately 39.2%[14] - The company had an accumulated deficit of $307.5 million as of September 30, 2025, up from $252.8 million as of December 31, 2024[28] - As of September 30, 2025, the company had $295.9 million in cash, cash equivalents, and marketable securities, with an accumulated deficit of $307.5 million[166] - The company has $4.1 million in non-cancellable lease obligations related to its Emeryville Lease, with $0.6 million due within the next 12 months[182] Revenue Recognition and Collaboration - The company has not generated any product revenue to date and anticipates incurring additional losses until it can generate significant sales[27] - The company recognized collaboration revenue of $5.9 million under the Novartis Agreement for the nine months ended September 30, 2025, with no revenue recognized in the same period of 2024[96] - The company entered into a collaboration agreement with Novartis, which includes potential payments of up to $550 million in future milestones[94] - The company evaluates collaboration agreements under ASC 606 and ASC 808 to determine the appropriate accounting treatment for multiple performance obligations[194] - The company recognizes revenue based on the satisfaction of performance obligations as outlined in ASC 606, impacting revenue recognition timing[186] Future Outlook and Plans - The company plans to finance its cash needs through equity offerings, debt financings, or other capital sources until it can generate substantial product revenues[30] - The company expects existing cash and marketable securities to fund operations through 2029, although this estimate is based on assumptions that may prove incorrect[177] - The company expects research and development expenses to continue to increase substantially as it progresses BGE-102 into additional clinical trials[137] - The company plans to file INDs for novel apelin receptor APJ agonists by the end of 2026[113] - The company expects to incur significant expenses related to developing commercialization capabilities for future product candidates if approved[120] Clinical Development - The lead product candidate, BGE-102, is being developed for obesity and cardiovascular risk factors, showing significant weight loss in preclinical models[24] - The first patient was dosed in the Phase 1 clinical trial for BGE-102 in August 2025, with initial data anticipated by year-end 2025[112] - The company discontinued its Phase 2 clinical trial for azelaprag in December 2024 due to liver transaminitis observed in some subjects[211] - The company has not completed any clinical trials beyond Phase 1b and has no products approved for commercial sale, making it difficult for investors to evaluate its business viability[208] - The transition from a research and development focus to supporting commercial activities has not been successfully demonstrated by the company[212] Capital and Funding - The company has raised approximately $559.2 million in gross proceeds since inception through various securities offerings[117] - The company has raised a total of $293.8 million from redeemable convertible preferred stock sales, $26.4 million from convertible notes, $238.3 million from common stock sales, and $0.7 million from stock option exercises as of September 30, 2025[210] - The company incurred net cash used in operating activities of $53.4 million for the nine months ended September 30, 2025, compared to $46.4 million for the same period in 2024[22] Risks and Challenges - The company has incurred significant operating losses since its inception and expects to continue incurring substantial losses for the foreseeable future[208] - The company requires substantial additional capital to finance operations and achieve its goals, with potential delays or reductions in research and development if capital is not raised[208] - The company faces unforeseen expenses and risks commonly experienced by biopharmaceutical companies[212] - The company is subject to risks related to securities litigation, which could divert management attention and incur significant costs[208]

Financial Performance - For the three months ended September 30, 2025, net sales increased 5.4% to $553.4 million from $524.8 million in the same period in 2024[120]. - Orders for the three months ended September 30, 2025 increased 15.7% to $491.4 million from $424.7 million for the same period in 2024[117]. - Gross profit for the three months ended September 30, 2025 increased 17.1% to $102.6 million compared to $87.6 million for the same period in 2024[124]. - Consolidated net sales for the nine months ended September 30, 2025 decreased 1.2% to $1,563.8 million from $1,582.0 million for the same period in 2024[123]. - Gross profit percentage for the three months ended September 30, 2025 increased 180 basis points to 18.5% compared to 16.7% for the same period in 2024[125]. - Orders for the nine months ended September 30, 2025 increased 10.5% to $1,555.6 million from $1,407.2 million for the same period in 2024[118]. - The Company reported net income of $5.0 million for the three months ended September 30, 2025, compared to a net loss of $(7.0) million in the same period of 2024[166]. - Operating income for the trailing twelve months ended September 30, 2025, was $49.8 million, showing a positive trend in operational performance[163]. Expenses and Costs - Engineering, selling, and administrative expenses for the three months ended September 30, 2025 increased 5.7% to $83.4 million from $78.9 million for the same period in 2024[128]. - Interest expense for the three months ended September 30, 2025 was $9.8 million, a slight increase from $9.6 million for the same period in 2024[130]. - Other expense - net for the three months ended September 30, 2025, was $0.8 million, a decrease from $4.9 million in the same period of 2024, primarily due to lower currency losses[133]. - For the nine months ended September 30, 2025, other expense - net was $4.8 million, compared to $3.9 million for the same period in 2024, driven by $3.1 million in net currency losses[134]. - The provision for income taxes for the three months ended September 30, 2025, was $2.5 million, compared to a benefit of $0.3 million in 2024, reflecting changes in jurisdictional mix[135]. Segment Performance - Americas segment net sales increased by 6.7% to $306.4 million for the three months ended September 30, 2025, from $287.1 million in 2024, primarily due to higher non-new machine sales[138]. - EURAF segment net sales increased by 28.7% to $163.2 million for the three months ended September 30, 2025, from $126.8 million in 2024, driven by higher tower crane sales[142]. - MEAP segment net sales decreased by 24.4% to $83.8 million for the three months ended September 30, 2025, from $110.9 million in 2024, primarily due to lower new machine sales[146]. Cash Flow and Liquidity - Cash flows used for operating activities increased to $68.9 million for the nine months ended September 30, 2025, from $63.2 million in 2024, mainly due to a $43.2 million payment to settle a legal matter with the EPA[151]. - Net cash provided by financing activities increased to $95.9 million for the nine months ended September 30, 2025, from $81.0 million in 2024, primarily due to additional net borrowings under the ABL Revolving Credit Facility[153]. - The company's total liquidity as of September 30, 2025, was $212.7 million, down from $320.9 million as of December 31, 2024[154]. - As of September 30, 2025, total debt increased to $500.4 million from $390.2 million as of December 31, 2024, representing a 28.3% increase[158]. - Free cash flows for the nine months ended September 30, 2025, were $(93.6) million, slightly improved from $(97.6) million in the same period of 2024[168]. Capital and Investments - Capital expenditures for the nine months ended September 30, 2025, were $24.7 million, down from $34.4 million in the same period of 2024[168]. - The Company plans to opportunistically raise capital in the debt capital markets and bank credit markets[158]. - The Company’s Adjusted ROIC as of September 30, 2025, was 4.8%, indicating the efficiency of capital utilization[162]. - For the three months ended September 30, 2025, adjusted EBITDA was $34.1 million, with an adjusted EBITDA margin of 6.2%[166]. Compliance and Risk Management - The Company was in compliance with all covenants related to its debt instruments as of September 30, 2025[158]. - The company continues to assess the potential impact of tariffs and is evaluating mitigation strategies, including supply chain adjustments and pricing strategies[115].

Financial Performance - Net income rose to $8.9 million for the third quarter of 2025, a 29% increase from $6.9 million in the same period of 2024, driven by property acquisitions and higher rental income[242]. - Net income increased to $24.5 million, a rise of 23% compared to the previous year, driven by higher rental income[247]. - The Company reported net income of $24.5 million for the nine months ended September 30, 2025, compared to $19.9 million for the same period in 2024, representing a 23.5% increase[285]. - Funds from operations (FFO) for the nine months ended September 30, 2025, were $58.9 million, up from $44.6 million in 2024, indicating a 32.1% increase[285]. Revenue and Rental Income - Rental revenues increased by $10.3 million or 35% to $39.7 million for the three months ended September 30, 2025, primarily due to the acquisition of 27 additional properties and a new master lease in Kentucky[239]. - Total rental revenues increased by $28.3 million or 33% due to the net acquisition of 27 properties and renegotiation of certain master leases[243]. - The Company completed the acquisition of a skilled nursing facility with 112 licensed beds for $11.5 million, adding $1.3 million in initial annual base rents[230]. - On July 1, 2025, the Company acquired nine skilled nursing facilities for $59 million, increasing annual rents by $5.5 million[232]. Expenses and Indebtedness - Interest expense increased by $4.4 million or 51% to $13.0 million, primarily due to new commercial bank loans and bond issuances[241]. - Depreciation and amortization expenses rose by $9.7 million or 39%, driven by the acquisition of new properties and lease rights[244]. - Interest expense, net, increased by $13.0 million or 54%, primarily due to additional interest incurred on a commercial bank loan and bond issuances[246]. - Total indebtedness as of September 30, 2025, was approximately $779.4 million, including $313.9 million in various bond series[253]. - The Company had a total gross note payable and senior debt of $779.4 million as of September 30, 2025, compared to $673.9 million at the end of 2024, reflecting a 15.7% increase[282]. Cash Flow - Cash provided by operating activities was $69.5 million for the nine months ended September 30, 2025, compared to $34.5 million in 2024[257]. - Cash used in investing activities totaled $107.3 million, primarily for the acquisition of 9 properties in Missouri and other locations[258]. Investment Strategy - The Company expects to continue diversifying its investments by tenant, facility type, and geography to enhance long-term stockholder value[227]. - The Company has a disciplined investment strategy focused on healthcare real estate assets to provide opportunities for dividend growth and asset appreciation[227]. - The company expects to meet long-term liquidity requirements through various sources, including future equity issuances and debt offerings[251]. - The company intends to distribute at least 90% of its REIT taxable income to stockholders annually[248]. Compliance and Controls - The Company is in compliance with financial covenants, including a maximum indebtedness to EBITDA ratio of 8.0 to 1 and a minimum GAAP equity of $20.0 million as of September 30, 2025[266][267]. - As of September 30, 2025, the Chief Executive Officer and Chief Financial Officer concluded that the company's disclosure controls and procedures were effective at the reasonable assurance level[293]. - There were no changes in internal control over financial reporting during the quarter ended September 30, 2025, that materially affected the internal control[294]. Legal Matters - The company is not currently a party to any material legal proceedings that are not covered by insurance, with previous complaints dismissed for lack of jurisdiction[296][298]. Property Transactions - The Company sold a property in Michigan for $2.7 million, resulting in a loss of $0.01 million[233]. - The Company foreclosed and sold four properties at auction for a total of $4.4 million in July 2022, and took title of a fifth property with an estimated fair value of $1.2 million in December 2022[302]. - The Company expects to close the acquisition of a skilled nursing facility for $3.0 million, with initial annual base rents of $0.3 million and 3% annual rent increases[287]. Debt Instruments - As of September 30, 2025, the Company had outstanding Series A Bonds totaling NIS 302.2 million ($91.4 million) and Series B Bonds totaling NIS 312.0 million ($94.4 million)[271][272]. - The Series D Bonds had an outstanding principal balance of approximately NIS 175.8 million ($53.2 million) as of September 30, 2025[279]. - The Company issued additional Series C Bonds totaling NIS 62.0 million ($16.6 million) in October 2024 at a price of 99.3%[274]. - The Company has $161.8 million (20.8% of total debt) in floating rate debt, which is subject to interest rate risk based on one-month SOFR[290]. - The Company incurred offering and issuance costs of approximately $2.5 million for the Series B Bonds issued in June 2025[272].

Financial Performance - For the three months ended September 30, 2025, net income was $34.962 million, an increase from $32.590 million in the same period of 2024, representing a growth of 7.3%[80] - The company reported earnings per share (diluted) of $0.91 for the three months ended September 30, 2025, compared to $0.85 for the same period in 2024[80] - Average tangible shareholders' equity was $1.087 billion for the three months ended September 30, 2025, compared to $977.999 million in the same period of 2024[77] - Return on average tangible shareholders' equity (non-GAAP) was 12.81% for the three months ended September 30, 2025, down from 13.35% in the same period of 2024[77] - Total assets increased to $9,717.7 million as of September 30, 2025, compared to $9,573.4 million as of September 30, 2024[1] - Total assets of the company reached $9.800 billion as of September 30, 2025, compared to $9.620 billion in the same period in 2024[90] Income and Expenses - Net interest income increased by $4.8 million, or 5.64%, for the three months ended September 30, 2025, compared to the same period in 2024[81] - Noninterest income increased by $1.9 million for the three months ended September 30, 2025, primarily due to no security losses in 2025 versus $2.2 million in losses in 2024[83] - Noninterest expense rose by $1.0 million, or 1.83%, for the three months ended September 30, 2025, with salaries and employee benefits increasing by $0.9 million due to merit increases and higher medical costs[84] - The effective tax rate decreased to 20.2% for the three months ended September 30, 2025, from 21.4% in the same period in 2024, attributed to increased low-income housing tax credits[85] Interest Income and Margin - The net interest margin (NIM) on a fully taxable equivalent (FTE) basis increased to 3.93% for the three months ended September 30, 2025, up from 3.82% in the same period of 2024[81] - Net interest income for the three months ended September 30, 2025, was $89.843 million, compared to $85.148 million for the same period in 2024, reflecting a net interest margin of 3.93% versus 3.82%[90] - Total interest and dividend income for the three months ended September 30, 2025, was $131.623 million, slightly up from $131.474 million in the same period of 2024[76] Loans and Credit Losses - The provision for credit losses increased to $2.8 million for the three months ended September 30, 2025, compared to a negative $0.4 million in the same period of 2024[82] - Net loan charge-offs were $2.4 million and $3.5 million for the three and nine months ended September 30, 2025, compared to $2.1 million and $8.3 million for the same periods in 2024[98] - Total portfolio loans increased by $238.0 million to $8.0 billion at September 30, 2025, with the commercial loan portfolio increasing by $158.8 million and the consumer loan portfolio increasing by $79.3 million[103] - The allowance for credit losses (ACL) decreased to $98.2 million, or 1.23% of total portfolio loans, down from $101.5 million, or 1.31%, at December 31, 2024[117] Deposits and Borrowings - Total deposits increased by $138.8 million to $7.9 billion at September 30, 2025, with customer deposits increasing by $163.6 million to $7.7 billion[105] - Average interest-bearing deposits increased to $5.779 billion for the three months ended September 30, 2025, with an average rate of 2.74%, compared to $5.555 billion and 3.04% in 2024[90] - Total borrowings decreased to $235.3 million at September 30, 2025, down from $250.3 million at December 31, 2024[123] Risk Management and Capital - The company implemented various ALCO strategies to manage interest rate and liquidity risks, aiming to maintain an acceptable level of net interest income[88] - Capital ratios for S&T Bancorp, Inc. exceeded well-capitalized regulatory guidelines, with total capital to risk-weighted assets at 16.63% as of September 30, 2025, compared to 16.49% at December 31, 2024[132] - The company continuously monitors interest rate risk through ALCO, which conducts rate shock analyses, EVE analyses, and stress tests[135] Strategic Priorities - The strategic priorities for 2025 and beyond include growing the deposit franchise and enhancing core profitability[79] - The company has filed a shelf registration statement allowing for the issuance of various securities for general corporate purposes, including possible acquisitions and stock repurchases[132]